AU2011288876B2 - Phthalazinone ketone derivative, preparation method thereof, and pharmaceutical use thereof - Google Patents

Phthalazinone ketone derivative, preparation method thereof, and pharmaceutical use thereof Download PDF

Info

Publication number
AU2011288876B2
AU2011288876B2 AU2011288876A AU2011288876A AU2011288876B2 AU 2011288876 B2 AU2011288876 B2 AU 2011288876B2 AU 2011288876 A AU2011288876 A AU 2011288876A AU 2011288876 A AU2011288876 A AU 2011288876A AU 2011288876 B2 AU2011288876 B2 AU 2011288876B2
Authority
AU
Australia
Prior art keywords
group
formula
compounds
heterocyclyl
pyrazine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2011288876A
Other languages
English (en)
Other versions
AU2011288876A2 (en
AU2011288876A1 (en
Inventor
Yang Chen
Xiangqin Li
Xin Li
Pengcho Tang
Bin Wang
Zhe ZHU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hengrui Medicine Co Ltd
Original Assignee
Jiangsu Hengrui Medicine Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co Ltd filed Critical Jiangsu Hengrui Medicine Co Ltd
Publication of AU2011288876A1 publication Critical patent/AU2011288876A1/en
Publication of AU2011288876A2 publication Critical patent/AU2011288876A2/en
Application granted granted Critical
Publication of AU2011288876B2 publication Critical patent/AU2011288876B2/en
Assigned to JIANGSU HENGRUI MEDICINE CO., LTD. reassignment JIANGSU HENGRUI MEDICINE CO., LTD. Request for Assignment Assignors: JIANGSU HANSOH PHARMACEUTICAL CO., LTD.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2011288876A 2010-08-09 2011-07-26 Phthalazinone ketone derivative, preparation method thereof, and pharmaceutical use thereof Active AU2011288876B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201010248307.5 2010-08-09
CN2010102483075A CN102372716A (zh) 2010-08-09 2010-08-09 酞嗪酮类衍生物、其制备方法及其在医药上的应用
PCT/CN2011/001223 WO2012019427A1 (zh) 2010-08-09 2011-07-26 酞嗪酮类衍生物、其制备方法及其在医药上的应用

Publications (3)

Publication Number Publication Date
AU2011288876A1 AU2011288876A1 (en) 2013-01-31
AU2011288876A2 AU2011288876A2 (en) 2013-02-21
AU2011288876B2 true AU2011288876B2 (en) 2014-08-21

Family

ID=45567315

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2011288876A Active AU2011288876B2 (en) 2010-08-09 2011-07-26 Phthalazinone ketone derivative, preparation method thereof, and pharmaceutical use thereof

Country Status (15)

Country Link
US (2) US9273052B2 (cg-RX-API-DMAC10.html)
EP (1) EP2604610B1 (cg-RX-API-DMAC10.html)
JP (1) JP5808408B2 (cg-RX-API-DMAC10.html)
KR (1) KR101829940B1 (cg-RX-API-DMAC10.html)
CN (2) CN102372716A (cg-RX-API-DMAC10.html)
AU (1) AU2011288876B2 (cg-RX-API-DMAC10.html)
BR (1) BR112013002220B1 (cg-RX-API-DMAC10.html)
CA (1) CA2806324C (cg-RX-API-DMAC10.html)
ES (1) ES2582315T3 (cg-RX-API-DMAC10.html)
HU (1) HUE029275T2 (cg-RX-API-DMAC10.html)
PL (1) PL2604610T3 (cg-RX-API-DMAC10.html)
PT (1) PT2604610T (cg-RX-API-DMAC10.html)
RU (1) RU2564527C2 (cg-RX-API-DMAC10.html)
UA (1) UA111161C2 (cg-RX-API-DMAC10.html)
WO (1) WO2012019427A1 (cg-RX-API-DMAC10.html)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102898377B (zh) * 2012-02-14 2016-01-20 南京圣和药业股份有限公司 一类酞嗪酮衍生物及其用途
CN102702108A (zh) * 2012-06-27 2012-10-03 上海大学 1,2-二氢酞嗪类化合物及其合成方法
CN103570725B (zh) * 2012-08-01 2017-03-22 中国科学院上海药物研究所 哌嗪并三唑类化合物及其制备方法和用途
CN102863393A (zh) * 2012-09-26 2013-01-09 上海大学 1,2-二氢酞嗪类化合物及其合成方法
MX2015006780A (es) * 2012-12-31 2015-08-06 Cadila Healthcare Ltd Derivados de ftalazin-1-(2h)-ona sustituida.
KR101670126B1 (ko) 2013-09-13 2016-10-27 일동제약(주) 신규 프탈라지논 유도체 및 그 제조방법
UY35834A (es) 2013-11-14 2015-05-29 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Piperazinas de pirazolo sustituido como inhibidores de caseína quinasa 1 delta y epsilon
WO2017013237A1 (en) 2015-07-23 2017-01-26 Institut Curie Use of a combination of dbait molecule and parp inhibitors to treat cancer
CN114702495A (zh) 2015-11-20 2022-07-05 福马治疗有限公司 作为泛素-特异性蛋白酶1抑制剂的嘌呤酮
CN106749261A (zh) * 2015-11-23 2017-05-31 中国科学院上海药物研究所 一类取代三唑并哌嗪类parp抑制剂及其制备方法和用途
CN107207504B (zh) * 2015-12-16 2020-03-10 四川科伦博泰生物医药股份有限公司 酞嗪酮衍生物、其制备方法及用途
US10722484B2 (en) 2016-03-09 2020-07-28 K-Gen, Inc. Methods of cancer treatment
TWI771344B (zh) * 2016-12-01 2022-07-21 大陸商江蘇恆瑞醫藥股份有限公司 一種vegfr抑制劑與parp抑制劑聯合在製備治療胃癌的藥物中的用途
WO2018162439A1 (en) 2017-03-08 2018-09-13 Onxeo New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule
AR111295A1 (es) 2017-03-20 2019-06-26 Forma Therapeutics Inc Composiciones de pirrolopirrol como activadores de piruvato quinasa (pkr)
EP3609897A1 (en) 2017-04-12 2020-02-19 H. Hoffnabb-La Roche Ag A method for labeling of aldehyde containing target molecules
CA3073613A1 (en) * 2017-08-24 2019-02-28 Jiangsu Hengrui Medicine Co., Ltd. Crystal form of parp-1 inhibitor and preparation method therefor
MX2020005659A (es) * 2017-12-06 2020-08-20 Jiangsu Hengrui Medicine Co Uso de un inhibidor de parp en el tratamiento del cancer de ovario o cancer de mama resistente a la quimioterapia.
AU2019207072A1 (en) 2018-01-09 2020-07-16 Jiangsu Hengrui Medicine Co., Ltd. Method for preparing PARP inhibitor and intermediate thereof
WO2019145214A1 (en) 2018-01-26 2019-08-01 Recordati Industria Chimica E Farmaceutica S.P.A TRIAZOLE, IMIDAZOLE AND PYRROLE CONDENSED PIPERAZINE DERIVATIVES AND THEIR USE AS MODULATORS OF mGlu5 RECEPTORS
CA3129516A1 (en) * 2018-02-28 2019-09-06 The Trustees Of The University Of Pennsylvania Low affinity poly(ad-ribose) polymerase 1 dependent cytotoxic agents
WO2019175132A1 (en) 2018-03-13 2019-09-19 Onxeo A dbait molecule against acquired resistance in the treatment of cancer
CA3095367A1 (en) * 2018-03-29 2019-10-03 Board Of Regents, The University Of Texas System Imidazopiperazine inhibitors of transcription activating proteins
WO2020061255A1 (en) 2018-09-19 2020-03-26 Forma Therapeutics, Inc. Activating pyruvate kinase r
US20200129485A1 (en) 2018-09-19 2020-04-30 Forma Therapeutics, Inc. Treating sickle cell disease with a pyruvate kinase r activating compound
WO2020083187A1 (zh) * 2018-10-22 2020-04-30 江苏恒瑞医药股份有限公司 一种ar拮抗剂联合parp抑制剂在制备治疗前列腺癌的药物中的用途
WO2020098774A1 (zh) * 2018-11-16 2020-05-22 江苏恒瑞医药股份有限公司 一种包含parp抑制剂的药物组合物
TW202110448A (zh) * 2019-05-28 2021-03-16 大陸商江蘇恆瑞醫藥股份有限公司 Parp抑制劑聯合vegfr抑制劑用於治療卵巢癌或乳腺癌的用途
MX2022003025A (es) 2019-09-19 2022-04-07 Forma Therapeutics Inc Activacion de la piruvato cinasa r.
CN112870365A (zh) * 2019-11-29 2021-06-01 江苏恒瑞医药股份有限公司 Ezh2抑制剂和/或parp抑制剂与化疗药物联合在制备治疗肿瘤药物中的用途
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
KR102913343B1 (ko) 2020-04-21 2026-01-15 아이디언스 주식회사 프탈라지논 화합물의 결정형
WO2021214502A1 (en) 2020-04-21 2021-10-28 Idience Co., Ltd. Process for preparing a phthalazinone derivative and intermediates thereof
CN111732594B (zh) * 2020-08-18 2022-03-04 苏州富士莱医药股份有限公司 一种氟唑帕利的制备方法
JP7777131B2 (ja) 2020-10-02 2025-11-27 ボード オブ レジェンツ,ザ ユニバーシティ オブ テキサス システム 転写活性化タンパク質のイミダゾピペラジン阻害剤
KR20230080441A (ko) 2020-10-02 2023-06-07 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 전사 활성화 단백질의 이미다조피페라진 억제제
US12059419B2 (en) 2020-10-16 2024-08-13 Idience Co., Ltd. Pharmaceutical composition comprising phthalazinone derivatives
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R
AU2022280845A1 (en) * 2021-05-24 2023-12-14 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Nitrogen-containing heterocyclic compound, preparation method therefor, and application thereof in medicines
WO2023288002A1 (en) * 2021-07-16 2023-01-19 Oregon Health & Science University Phthalazinone-based parp-1 inhibitors
JP2024528021A (ja) * 2021-07-29 2024-07-26 上海齊魯制藥研究中心有限公司 新規なparp7阻害剤及びその使用
CN115650988B (zh) * 2022-10-27 2024-09-13 江苏恒瑞医药股份有限公司 一种parp抑制剂的制备方法
KR20250103773A (ko) * 2022-11-23 2025-07-07 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 질소 함유 헤테로시클릭계 화합물의 약학적으로 사용 가능한 염, 결정형 및 제조 방법
TW202502341A (zh) * 2023-03-13 2025-01-16 大陸商江蘇豪森藥業集團有限公司 哌啶烯類化合物在製備治療癌症的藥物中的應用
WO2024261243A1 (en) 2023-06-21 2024-12-26 Hemispherian As Combination comprising a deoxycytidine derivative and a parp inhibitor for use in a method of treating hr proficient cancer

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004080976A1 (en) * 2003-03-12 2004-09-23 Kudos Pharmaceuticals Limited Phthalazinone derivatives
WO2007138351A2 (en) * 2006-05-31 2007-12-06 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Pyridinone and pyridazinone derivatives as inhibitors of poly(adp-ribose)polymerase (parp)
US20080161280A1 (en) * 2006-12-28 2008-07-03 Abbott Laboratories Inhibitors of poly(adp-ribose)polymerase
US20080200469A1 (en) * 2003-03-12 2008-08-21 Kudos Pharmaceuticals Limited Phthalazinone derivatives
WO2009004356A1 (en) * 2007-07-05 2009-01-08 Astrazeneca Ab Phthalazinone derivatives as inhibitors of parp-1

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU228960B1 (hu) 2000-10-30 2013-07-29 Kudos Pharm Ltd Ftalazinon-származékok
KR100663147B1 (ko) * 2002-02-19 2007-02-28 오노 야꾸힝 고교 가부시키가이샤 축합 피리다진 유도체 화합물 및 이를 유효 성분으로서함유하는 약제
AR043443A1 (es) 2003-03-07 2005-07-27 Merck & Co Inc Procedimiento de preparacion de tetrahidrotriazolopirazinas y productos intermedios
KR20070057859A (ko) 2004-08-26 2007-06-07 쿠도스 파마슈티칼스 리미티드 4-헤테로아릴메틸 치환된 프탈라지논 유도체
EP2190428A4 (en) 2007-08-21 2012-02-29 Merck Sharp & Dohme HETEROCYCLIC COMPOUNDS AS DIPEPTIDYLPEPTIDASE IV HEMMER FOR TREATMENT OR PREVENTION OF DIABETES
CN101468988A (zh) 2007-12-26 2009-07-01 上海恒瑞医药有限公司 哌嗪类衍生物,其制备方法及其在医药上的应用
JP2011509962A (ja) 2008-01-17 2011-03-31 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 置換スルホンアミド誘導体

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004080976A1 (en) * 2003-03-12 2004-09-23 Kudos Pharmaceuticals Limited Phthalazinone derivatives
US20080200469A1 (en) * 2003-03-12 2008-08-21 Kudos Pharmaceuticals Limited Phthalazinone derivatives
WO2007138351A2 (en) * 2006-05-31 2007-12-06 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Pyridinone and pyridazinone derivatives as inhibitors of poly(adp-ribose)polymerase (parp)
US20080161280A1 (en) * 2006-12-28 2008-07-03 Abbott Laboratories Inhibitors of poly(adp-ribose)polymerase
WO2009004356A1 (en) * 2007-07-05 2009-01-08 Astrazeneca Ab Phthalazinone derivatives as inhibitors of parp-1

Also Published As

Publication number Publication date
UA111161C2 (uk) 2016-04-11
CN102686591B (zh) 2014-03-19
ES2582315T3 (es) 2016-09-12
EP2604610A4 (en) 2013-12-25
US20160151367A1 (en) 2016-06-02
JP2013535491A (ja) 2013-09-12
EP2604610B1 (en) 2016-05-11
AU2011288876A2 (en) 2013-02-21
KR20130110149A (ko) 2013-10-08
BR112013002220B1 (pt) 2021-09-21
RU2564527C2 (ru) 2015-10-10
PT2604610T (pt) 2016-07-13
EP2604610A1 (en) 2013-06-19
CN102686591A (zh) 2012-09-19
CN102372716A (zh) 2012-03-14
HUE029275T2 (en) 2017-02-28
US9273052B2 (en) 2016-03-01
CA2806324C (en) 2019-02-19
US20130131068A1 (en) 2013-05-23
WO2012019427A8 (zh) 2012-05-10
AU2011288876A1 (en) 2013-01-31
CA2806324A1 (en) 2012-02-16
PL2604610T3 (pl) 2016-11-30
KR101829940B1 (ko) 2018-02-19
BR112013002220A2 (pt) 2016-05-24
RU2013106754A (ru) 2014-09-20
HK1174030A1 (en) 2013-05-31
JP5808408B2 (ja) 2015-11-10
US9566277B2 (en) 2017-02-14
WO2012019427A1 (zh) 2012-02-16

Similar Documents

Publication Publication Date Title
CA2806324C (en) Phthalazinone ketone derivative, preparation method thereof, and pharmaceutical use thereof
US20210238196A1 (en) Spiro aromatic ring compound and application thereof
JP6564406B2 (ja) カゼインキナーゼ1デルタ/イプシロン阻害剤としてのイミダゾ−ピリダジン誘導体
CN116157400B (zh) 杂环类衍生物及其制备方法和用途
CN113045559B (zh) 一种二芳基脲类PI3Kα/mTOR双靶点抑制剂及其药物组合物和应用
WO2013064083A1 (en) 1-(arylmethyl)-5,6,7,8-tetrahydroquinazoline-2,4-diones and analogs and the use thereof
TW201319067A (zh) 三唑并吡啶化合物
CN115677730B (zh) 8-氧-3-氮杂二环[3.2.1]辛烷类化合物或其盐及其制备方法和用途
WO2023241322A1 (en) Heterocyclic derivatives, compositions and uses thereof
JP7511933B2 (ja) Fgfrおよびその突然変異阻害剤、その製造方法と応用
JP2012512852A (ja) 6−シクロアミノ−2−チエニル−3−(ピリジン−4−イル)イミダゾ[1,2−b]−ピリダジンおよび6−シクロアミノ−2−フラニル−3−(ピリジン−4−イル)イミダゾ[1,2−b]−ピリダジンの誘導体、その調製ならびに治療的用途
WO2024104244A1 (zh) 草酸酰胺化合物、包含其的药物组合物及其制备方法和用途
TWI548637B (zh) 酞嗪酮類衍生物、其製備方法及其在醫藥上的應用
CN116836184A (zh) Wee1激酶抑制剂的制备及其应用
JP2024510520A (ja) ダブルリング雑環fgfr4阻害剤、ダブルリング雑環fgfr4阻害剤を含有する医薬組成物と製剤、及びその用途
RU2781100C1 (ru) Соединения со спиро- и ароматическими кольцами и их применение
TW202506680A (zh) 作為parp1抑制劑之雜環化合物
JP2026507185A (ja) Parp阻害剤としての置換窒素含有三環式化合物及びその使用
WO2023033741A1 (en) Compounds useful in modulation of ahr signalling
KR20250136774A (ko) 헤테로아릴 유도체 화합물 및 이의 용도
WO2022237844A1 (zh) 含吡嗪结构的吡咯并嘧啶衍生物
HK1174030B (en) Phthalazinone ketone derivative, preparation method thereof, and pharmaceutical use thereof

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 11 JAN

FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: JIANGSU HENGRUI MEDICINE CO., LTD.

Free format text: FORMER OWNER(S): JIANGSU HANSOH PHARMACEUTICAL CO., LTD.